Veracyte annual revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Veracyte Revenue Growth & History (VCYT)
Veracyte reported $517.1M in revenue for fiscal 2025, an increase of 16.01% from the previous fiscal year.
View full Veracyte company overviewVeracyte annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $517.1M | $71.4M | +16.01% |
| 2024 | 2024-12-31 | $445.8M | $84.7M | +23.46% |
| 2023 | 2023-12-31 | $361.1M | $64.5M | +21.76% |
| 2022 | 2022-12-31 | $296.5M | $77.0M | +35.09% |
| 2021 | 2021-12-31 | $219.5M | $102.0M | +86.85% |
| 2020 | 2020-12-31 | $117.5M | −$2.9M | −2.40% |
| 2019 | 2019-12-31 | $120.4M | $28.4M | +30.82% |
| 2018 | 2018-12-31 | $92.0M | $20.1M | +27.87% |
| 2017 | 2017-12-31 | $72.0M | $6.9M | +10.55% |
| 2016 | 2016-12-31 | $65.1M | $15.6M | +31.48% |
| 2015 | 2015-12-31 | $49.5M | $11.3M | +29.62% |
| 2014 | 2014-12-31 | $38.2M | $16.3M | +74.51% |
| 2013 | 2013-12-31 | $21.9M | $10.3M | +88.20% |
| 2012 | 2012-12-31 | $11.6M | $9.0M | +339.62% |
| 2011 | 2011-12-31 | $2.6M | — | — |
Veracyte quarterly revenue
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $150.3M | $20.2M | +15.49% |
| Q1 2026 | 2026-03-31 | $139.1M | $24.6M | +21.49% |
| Q4 2025 | 2025-12-31 | $140.6M | $22.0M | +18.55% |
| Q3 2025 | 2025-09-30 | $131.9M | $16.0M | +13.82% |
| Q2 2025 | 2025-06-30 | $130.2M | $15.7M | +13.75% |
| Q1 2025 | 2025-03-31 | $114.5M | $17.6M | +18.20% |
| Q4 2024 | 2024-12-31 | $118.6M | $20.4M | +20.81% |
| Q3 2024 | 2024-09-30 | $115.9M | $25.8M | +28.58% |
| Q2 2024 | 2024-06-30 | $114.4M | $24.1M | +26.69% |
| Q1 2024 | 2024-03-31 | $96.8M | $14.4M | +17.50% |
| Q4 2023 | 2023-12-31 | $98.2M | $17.9M | +22.29% |
| Q3 2023 | 2023-09-30 | $90.1M | $14.5M | +19.20% |
| Q2 2023 | 2023-06-30 | $90.3M | $17.5M | +23.96% |
| Q1 2023 | 2023-03-31 | $82.4M | $14.6M | +21.60% |
| Q4 2022 | 2022-12-31 | $80.3M | $13.0M | +19.25% |
| Q3 2022 | 2022-09-30 | $75.6M | $15.2M | +25.21% |
| Q2 2022 | 2022-06-30 | $72.9M | $17.8M | +32.23% |
| Q1 2022 | 2022-03-31 | $67.8M | $31.1M | +84.68% |
| Q4 2021 | 2021-12-31 | $67.3M | $32.8M | +94.97% |
| Q3 2021 | 2021-09-30 | $60.4M | $29.2M | +93.98% |
| Q2 2021 | 2021-06-30 | $55.1M | $34.4M | +166.16% |
| Q1 2021 | 2021-03-31 | $36.7M | $5.6M | +17.93% |
| Q4 2020 | 2020-12-31 | $34.5M | $4.8M | +16.17% |
| Q3 2020 | 2020-09-30 | $31.1M | $148,000 | +0.48% |
| Q2 2020 | 2020-06-30 | $20.7M | −$9.4M | −31.30% |
| Q1 2020 | 2020-03-31 | $31.1M | $1.6M | +5.39% |
| Q4 2019 | 2019-12-31 | $29.7M | $4.0M | +15.46% |
| Q3 2019 | 2019-09-30 | $31.0M | $7.5M | +31.99% |
| Q2 2019 | 2019-06-30 | $30.1M | $7.4M | +32.46% |
| Q1 2019 | 2019-03-31 | $29.5M | $9.5M | +47.34% |
| Q4 2018 | 2018-12-31 | $25.8M | $6.2M | +31.40% |
| Q3 2018 | 2018-09-30 | $23.5M | $5.9M | +33.95% |
| Q2 2018 | 2018-06-30 | $22.8M | $4.3M | +23.61% |
| Q1 2018 | 2018-03-31 | $20.0M | $3.6M | +21.96% |
| Q4 2017 | 2017-12-31 | $19.6M | $1.3M | +7.33% |
| Q3 2017 | 2017-09-30 | $17.5M | −$1.1M | −5.83% |
| Q2 2017 | 2017-06-30 | $18.4M | $3.7M | +25.42% |
| Q1 2017 | 2017-03-31 | $16.4M | $2.9M | +21.27% |
| Q4 2016 | 2016-12-31 | $18.3M | $4.2M | +30.02% |
| Q3 2016 | 2016-09-30 | $18.6M | $6.3M | +50.81% |
| Q2 2016 | 2016-06-30 | $14.7M | $2.8M | +23.24% |
| Q1 2016 | 2016-03-31 | $13.6M | $2.3M | +20.79% |
| Q4 2015 | 2015-12-31 | $14.0M | $1.8M | +15.11% |
| Q3 2015 | 2015-09-30 | $12.3M | $2.5M | +25.38% |
| Q2 2015 | 2015-06-30 | $11.9M | $3.2M | +37.24% |
| Q1 2015 | 2015-03-31 | $11.2M | $3.7M | +50.05% |
| Q4 2014 | 2014-12-31 | $12.2M | $5.4M | +78.40% |
| Q3 2014 | 2014-09-30 | $9.8M | $4.2M | +75.87% |
| Q2 2014 | 2014-06-30 | $8.7M | $3.6M | +71.21% |
| Q1 2014 | 2014-03-31 | $7.5M | $3.1M | +70.53% |
| Q4 2013 | 2013-12-31 | $6.8M | $2.4M | +53.42% |
| Q3 2013 | 2013-09-30 | $5.6M | $2.4M | +73.51% |
| Q2 2013 | 2013-06-30 | $5.1M | $2.6M | +104.44% |
| Q1 2013 | 2013-03-31 | $4.4M | $2.9M | +198.64% |
| Q4 2012 | 2012-12-31 | $4.5M | — | — |
| Q3 2012 | 2012-09-30 | $3.2M | — | — |
| Q2 2012 | 2012-06-30 | $2.5M | — | — |
| Q1 2012 | 2012-03-31 | $1.5M | — | — |
Veracyte revenue growth trends
Over the last five reported fiscal years, revenue grew from $117.5M to $517.1M, a compound annual growth rate of 34.50%. Veracyte's latest reported quarter, Q2 2026, generated $150.3M in revenue, an increase of 15.49% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Veracyte source filings ↗Community posts
New Decipher analysis links genomic scores to benefit from added hormone therapy
Veracyte ($VCYT) reported a retrospective analysis of samples from 395 participants in a randomized Phase III prostate-cancer trial. Patients with intermediate or high Decipher genomic scores had an eight-percentage-point reduction in ten-y ...
